作者
Ella J Daly, Madhukar H Trivedi, Adam Janik, Honglan Li, Yun Zhang, Xiang Li, Rosanne Lane, Pilar Lim, Anna R Duca, David Hough, Michael E Thase, John Zajecka, Andrew Winokur, Ilona Divacka, Andrea Fagiolini, Wiesław J Cubała, István Bitter, Pierre Blier, Richard C Shelton, Patricio Molero, Husseini Manji, Wayne C Drevets, Jaskaran B Singh
发表日期
2019/9/1
期刊
JAMA psychiatry
卷号
76
期号
9
页码范围
893-903
出版商
American Medical Association
简介
Importance
Controlled studies have shown short-term efficacy of esketamine for treatment-resistant depression (TRD), but long-term effects remain to be established.
Objective
To assess the efficacy of esketamine nasal spray plus an oral antidepressant compared with an oral antidepressant plus placebo nasal spray in delaying relapse of depressive symptoms in patients with TRD in stable remission after an induction and optimization course of esketamine nasal spray plus an oral antidepressant.
Design, Setting, and Participants
In this phase 3, multicenter, double-blind, randomized withdrawal study conducted from October 6, 2015, to February 15, 2018, at outpatient referral centers, 705 adults with prospectively confirmed TRD were enrolled; 455 entered the optimization phase and were treated with esketamine nasal spray (56 or 84 mg) plus an oral antidepressant. After 16 weeks of esketamine treatment, 297 who …
学术搜索中的文章
EJ Daly, MH Trivedi, A Janik, H Li, Y Zhang, X Li… - JAMA psychiatry, 2019